Jump to content

talabostat on clinical hold by FDA


Recommended Posts

May 21 (Reuters) - Point Therapeutics Inc. (POTP.O: Quote, Profile, Research said U.S. regulators have put its late-stage studies for experimental lung cancer drug talabostat on clinical hold based on interim results.

The bipharmaceutical company said its independent data monitoring committee recommended stopping the studies because neither the main nor secondary goal was met.

The company was conducting two late-stage trials with talabostat in combination with another cancer drug.

Reuters Pictures

Editors Choice: Best pictures

from the last 24 hours.

View Slideshow

One study was conducted in combination with Eli Lilly and Co.'s (LLY.N: Quote, Profile, Research pemetrexed and the other with Sanofi-Aventis' (SASY.PA: Quote, Profile, Research docetaxal.

For both studies, the main goal was progression-free survival, which refers to the probability that a patient will remain alive without the disease getting worse. The secondary goal was overall survival.

In March, the company said its experimental pancreatic cancer drug study failed to meet its mail goal of six-month survival.

Shares were trading at 13 cents in pre-market electronic trade, after closing at 44 cents Friday on the Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore)

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.